Skip to content
Screener

Aardvark Therapeutics, Inc. AARD Q3 2025 earnings

Reported November 13, 2025 · Before market open

Revenue-
EPS-$0.75Beat by $0.05
EPS estimate-$0.80

Next report

Nov 12, 2026 (in a month)
EPS estimate-$0.74

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$17.7M-248%
Net income-$16.3M-290%
EPS (diluted)-$0.75+28.6%

Balance sheet

See full
Cash & equivalents$39.3M—
Total debt$545.0K—
Total equity$122.4M+365%
Total assets$133.2M—

Cash flow

See full
Operating cash flow-$16.1M-308%
CapEx$4.0K-20.0%
Free cash flow-$16.1M-307%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$288.3M—
Enterprise value$249.56M—

Returns & leverage

See full
Debt / equity0×—
Current ratio12×—

FAQ

When did Aardvark Therapeutics, Inc. report Q3 2025 earnings?
Aardvark Therapeutics, Inc. (AARD) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Aardvark Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Aardvark Therapeutics, Inc. reported revenue of - and eps of $-0.75 for Q3 2025.
Did Aardvark Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.80 by $0.05.
How did Aardvark Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 131.5% from $-0.32.
Where can I find Aardvark Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-280235) and the 10-Q periodic report (0001193125-25-280260) directly on SEC EDGAR. The filing index links above go to sec.gov.